Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials
3 days ago · Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell ...
Merck Provides Update on KeyVibe and KEYFORM Clinical …
2 days ago · About KeyVibe-007 KeyVibe-007 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. ...
Merck Discontinues Certain Cancer Candidate Trials After Futility …
1 day ago · Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell ...
Merck Discontinues Certain Cancer Candidate Trials After Futility ...
2 days ago · Considering the totality of data from the Phase 3 KeyVibe studies, including the efficacy outcomes from KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the Phase 3 KeyVibe-006 ...
Vibostolimab/Favezelimab Clinical Programs in NSCLC/Lymphoma …
2 days ago · The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued. The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued. ... News release. Merck. May 13, 2024. Accessed December 17, 2024. https://tinyurl.com ...
Merck Axes Two Cancer Candidates After Disappointing Late
1 day ago · “Considering the totality of the data from the Phase 3 KeyVibe studies, including the efficacy outcomes from KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the Phase 3 KeyVibe-006 trial and other vibostolimab studies,” Merck’s news release stated. Monday’s announcement ends a disappointing run for vibostolimab.
Merck Ends Development of Two Experimental Cancer Drugs
1 day ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. ... KeyVibe-003 and KeyVibe-007, conducted by an independent data monitoring committee (IDMC ...
Merck Provides Update on KeyVibe and KEYFORM Clinical
3 days ago · About KeyVibe-007 KeyVibe-007 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT05226598) evaluating the fixed-dose combination of vibostolimab and pembrolizumab with chemotherapy in treatment-naïve patients with metastatic NSCLC. The primary endpoint is OS in participants with PD-L1 TPS ≥1%.
Merck & Co., Inc. Provides Update on KeyVibe and KEYFORM …
2 days ago · Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung cancer (NSCLC), based on the recommendation of an independent Data Monitoring Committee (DMC). ... News Merck & Co., Inc.
Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical …
2 days ago · FREE Breaking News Alerts from StreetInsider.com! E-mail Address. StreetInsider.com Top Tickers, 12/16/2024 ... About KeyVibe-007 KeyVibe-007 is a randomized, double-blind Phase 3 trial ...
- Some results have been removed